EHA 2024 | Mezigdomide, dexamethasone and tazemetostat in patients with multiple myeloma in the CA057-003 trial
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, presents preliminary findings from a cohort of patients with multiple myeloma (MM) treated with the combination of mezigdomide, dexamethasone and tazemetostat in the CA057-003 trial (NCT05372354). Of the 13 patients treated, data indicate the combination is safe, with no new safety signals compared to single-agent mezigdomide. More than half of the patients responded, marking a promising first step towards an effective mezigdomide-based combination. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
